Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Vascular Endothelial Growth Factor Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vascular Endothelial Growth Factor Inhibitors: Overview
Angiogenesis, or formation of new blood capillaries from preexisting vessels, plays both beneficial and damaging roles in the organism. It is a result of a complex balance of positive and negative regulators, and vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors involved in tumor angiogenesis. VEGF increases vascular permeability, which might facilitate tumor dissemination via the circulation causing a greater delivery of oxygen and nutrients; it recruits circulating endothelial precursor cells, and acts as a survival factor for immature tumor blood vessels. The endotheliotropic activities of VEGF are mediated through the VEGF-specific tyrosine-kinase receptors: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF and its receptors play a central role in tumor angiogenesis, and therefore the blockade of this pathway is a promising therapeutic strategy for inhibiting angiogenesis and tumor growth. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function.
'Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Endothelial Growth Factor Inhibitors pipeline landscape is provided which includes the disease overview and Vascular Endothelial Growth Factor Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Vascular Endothelial Growth Factor Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Endothelial Growth Factor Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Vascular Endothelial Growth Factor Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Endothelial Growth Factor Inhibitors Emerging Drugs
Further product details are provided in the report……..
Vascular Endothelial Growth Factor Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Endothelial Growth Factor Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Vascular Endothelial Growth Factor Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor Inhibitors drugs.
Vascular Endothelial Growth Factor Inhibitors Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Vascular Endothelial Growth Factor Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vascular Endothelial Growth Factor Inhibitors: Overview
Angiogenesis, or formation of new blood capillaries from preexisting vessels, plays both beneficial and damaging roles in the organism. It is a result of a complex balance of positive and negative regulators, and vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors involved in tumor angiogenesis. VEGF increases vascular permeability, which might facilitate tumor dissemination via the circulation causing a greater delivery of oxygen and nutrients; it recruits circulating endothelial precursor cells, and acts as a survival factor for immature tumor blood vessels. The endotheliotropic activities of VEGF are mediated through the VEGF-specific tyrosine-kinase receptors: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF and its receptors play a central role in tumor angiogenesis, and therefore the blockade of this pathway is a promising therapeutic strategy for inhibiting angiogenesis and tumor growth. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function.
'Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Endothelial Growth Factor Inhibitors pipeline landscape is provided which includes the disease overview and Vascular Endothelial Growth Factor Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Vascular Endothelial Growth Factor Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Endothelial Growth Factor Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Endothelial Growth Factor Inhibitors.
This segment of the Vascular Endothelial Growth Factor Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Endothelial Growth Factor Inhibitors Emerging Drugs
- KSI-301: Kodiak Sciences
- ONS-5010: Outlook Therapeutics
- ADVM-022: Adverum Biotechnologies
Further product details are provided in the report……..
Vascular Endothelial Growth Factor Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Endothelial Growth Factor Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vascular Endothelial Growth Factor Inhibitors
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Vascular Endothelial Growth Factor Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor Inhibitors drugs.
Vascular Endothelial Growth Factor Inhibitors Report Insights
- Vascular Endothelial Growth Factor Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vascular Endothelial Growth Factor Inhibitors drugs?
- How many Vascular Endothelial Growth Factor Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Endothelial Growth Factor Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Endothelial Growth Factor Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular Endothelial Growth Factor Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Adverum Biotechnologies
- Outlook Therapeutics
- Sandoz
- Boehringer Ingelheim
- Allarity Therapeutics
- Konruns Pharmaceutical
- Kodiak Sciences
- ADVM-022
- ONS-5010
- SOK583A1
- BI 836880
- Dovitinib
- CX1003
- KSI-301
- KSI-501
Introduction
Executive Summary
Vascular Endothelial Growth Factor Inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
KSI-301: Kodiak Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ADVM-022: Adverum Biotechnologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
CX1003: Konruns Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
KSI-501: Kodiak Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Endothelial Growth Factor Inhibitors Key Companies
Vascular Endothelial Growth Factor Inhibitors Key Products
Vascular Endothelial Growth Factor Inhibitors- Unmet Needs
Vascular Endothelial Growth Factor Inhibitors- Market Drivers and Barriers
Vascular Endothelial Growth Factor Inhibitors- Future Perspectives and Conclusion
Vascular Endothelial Growth Factor Inhibitors Analyst Views
Vascular Endothelial Growth Factor Inhibitors Key Companies
Appendix
Executive Summary
Vascular Endothelial Growth Factor Inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
KSI-301: Kodiak Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ADVM-022: Adverum Biotechnologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
CX1003: Konruns Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
KSI-501: Kodiak Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Endothelial Growth Factor Inhibitors Key Companies
Vascular Endothelial Growth Factor Inhibitors Key Products
Vascular Endothelial Growth Factor Inhibitors- Unmet Needs
Vascular Endothelial Growth Factor Inhibitors- Market Drivers and Barriers
Vascular Endothelial Growth Factor Inhibitors- Future Perspectives and Conclusion
Vascular Endothelial Growth Factor Inhibitors Analyst Views
Vascular Endothelial Growth Factor Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vascular Endothelial Growth Factor Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vascular Endothelial Growth Factor Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vascular Endothelial Growth Factor Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vascular Endothelial Growth Factor Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
